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was not protective of end-stage renal failure. We studied
another 75 patients who entered a randomized controlled
trial (37 were on treatment and 38 controls) from 1999 to
2000 and were followed up for 5 years. Leaving out patients
on combined therapy, we again found that patients on ACEI
alone had a significantly higher incidence of progression to
end-stage renal failure when compared to those on ATRA
alone (Table 1b).
It is our belief that ATRA is superior to ACEI. Apart from
its ability to reduce or block the effects of ACE, ATRA by
itself has other renoprotective abilities like reducing trans-
forming growth factor-b production in the glomerulus,
which causes mesangial cell proliferation and contraction. In
diabetic nephropathy and IgA nephropathy, mesangial cell
injury is one of the main events in glomerular injury leading
to glomerular sclerosis.3 It would be interesting for Suissa
and co-workers to examine their data regarding the role of
ATRA in preventing end-stage renal failure.
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To the Editor: Suissa et al.1 reported on the risk of renal
failure in diabetics treated with angiotensin-converting
enzyme (ACE) inhibitors. They used a nested case–control
design and thus excluded over 1800 patients from the final
analysis. It is not clear why the entire cohort could not have
been analyzed to address the issue of mortality. ACE
inhibitors are intentionally prescribed to reduce mortality2
and to prolong time to dialysis.3 It would be informative for
the readers if the authors presented data for these two
outcomes both separately and combined (e.g. death, dialysis,
or transplant) for those prescribed ACE inhibitors and those
not, using the entire cohort of 6102 patients. Only with this
information can the readers determine if their conclusions
are valid. As the authors themselves state ‘ACE inhibitors
prolong life, thus increasing the opportunity for end-stage
renal disease incidence’.1 In addition, a stepped-care
approach to hypertension was often used in the era of this
study.4 As such, ACE inhibitors may have been prescribed to
patients with difficult to control blood pressure. It would be
useful to know if the database had any blood pressure values
and if there were any differences between the groups, as the
severity of hypertension is arguably the single most
important factor for progression of diabetic nephropathy.
In view of the above comments, the conclusion that ACE
inhibitors may increase the risk of renal failure in diabetes
may not be justified.
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To the Editor: Recently, Suissa et al.1 reported that use of
ACE inhibitors (ACEi) by hypertensive diabetic patients is
not associated with a long-term decreased risk of end-stage
renal disease. They suggest that ACEi while providing an early
benefit to the kidney could in fact damage the kidney in the
longer term by mechanisms still unknown.
Experimental data from our group support the possibility
of such adverse effects of renin–angiotensin system blockade
Table 1 | (a) Anti-proteinuric response to ACEI/ATRA therapy
and (b) comparing ACEI with ATRA therapy among
37 patients
ACEI ATRA
(a)
Responders (n=9) 2 7
Non-responders (n=7) 6 1
Pearson’s w2 6.3 (Po0.02)
(b)
Normal renal function 1 16
ESRF 5 7
Pearson’s w2 5.5 (Po0.02)
ACEI, angiotensin-converting enzyme inhibitor; ATRA, angiotensin II receptor
antagonist; ESRF, end-stage renal failure.
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